Enliven Therapeutics

IPO

Small Molecule Kinase Inhibitors

Public · Boulder, United States · Founded 2019 · $305.0M raised

Headquarters
Boulder
Founded
2019
Business Model
B2B
Total Funding
$305.0M
Last Round
$165.0M Corporate RoundFeb 2023
Rounds
3
Type
Public

About

Enliven Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boulder, Colorado, founded in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel. The company discovers and develops small molecule kinase inhibitor therapies for cancer, including lead program ELVN-001 targeting BCR-ABL alongside a second program directed at HER2, designed to overcome resistance mechanisms seen with existing therapies as part of its mission to help patients not only live longer, but live better.

Summary

Enliven Therapeutics is a Biotech company based in Boulder, United States, founded in 2019. It has raised $305.0M in total across 3 rounds, most recently a $165.0M Corporate Round in Feb 2023. Investors include OrbiMed and Fairmount.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondary MarketJan 2024

Sign up to see all 4 events

Funding: Series A through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Enliven Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/enliven-therapeutics"><img src="https://indexed.vc/api/badge/company/enliven-therapeutics" alt="Enliven Therapeutics on Indexed.vc" width="260" height="76" /></a>